eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2021
vol. 7
 
Share:
Send email
Share:
abstract:
Original paper

Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term

Mahmoud Atamla
1
,
Johad Khoury
2
,
Ihab Dabbah
1
,
Rimma Kramsky
1
,
Afif Yaacob
1
,
Ella Veitsman
1
,
Tarek Saadi
1

  1. Rambam Health Care Campus, Israel
  2. Pulmonology Department, Lady Davis Carmel Medical Center, Israel
Clin Exp HEPATOL 2021; 7, 3: 258-263
DOI: https://doi.org/10.5114/ceh.2021.109192
Online publish date: 2021/09/20
View full text Get citation
 
PlumX metrics:
Introduction
Direct antiviral agents (DAAs) are new drugs for the treatment of chronic hepatitis C virus (HCV) infection. These drugs are very effective and well tolerated. HCV can cause liver disease as well as extrahepatic manifestations, including a profound negative impact on health-related quality of life (HRQL).

Aim of the study
To evaluate HRQL in the long term (> 6 months after finishing treatment) after successful treatment with DAAs. To the best of our knowledge, this is the first study that evaluates quality of life in the long term after DAA treatment.

Material and methods
This is an observational study which included 100 patients treated with DAAs for chronic HCV infection between January 2015 and August 2018. Patients were assigned randomly. The average time after finishing treatment was 29.96 months. The Liver Disease Symptom Index (LDSI) 2.0 Questionnaire was used to evaluate quality of life before and after treatment.

Results
Seven of 9 parameters of the LDSI 2.0 Questionnaire showed significant improvement in the long term after successful treatment with DAAs. Two parameters (arthralgia and jaundice) did not improve significantly. Quality of life improved in both males and females similarly. Improvement did not correlate with the severity of liver fibrosis.

Conclusions
Treatment with DAAs improves HRQL significantly in the long term.

keywords:

quality of life, HCV, hepatitis C virus, DAA, direct antiviral agent
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.